Drug
Sacituzumab Tirumotecan (SKB264)
Sacituzumab Tirumotecan (SKB264) is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_2
3
75%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Not yet recruiting3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 23 (75.0%)
N/A1 (25.0%)
Trials by Status
recruiting125%
not_yet_recruiting375%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_2
Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC
NCT07819578
not_yet_recruitingphase_2
Genitourinary Tumors With Sacituzumab Tirumotecan
NCT07716917
not_yet_recruitingphase_2
Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer
NCT07701122
recruitingnot_applicable
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
NCT07068542
Clinical Trials (4)
Showing 4 of 4 trials
NCT07819578Phase 2
Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC
NCT07716917Phase 2
Genitourinary Tumors With Sacituzumab Tirumotecan
NCT07701122Phase 2
Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer
NCT07068542Not Applicable
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4